|
17 Oct 2025 |
Dr. Reddy's Labs
|
Consensus Share Price Target
|
1240.20 |
1292.67 |
- |
4.23 |
hold
|
|
|
|
|
29 Jul 2022
|
Dr. Reddy's Labs
|
Prabhudas Lilladhar
|
1240.20
|
4750.00
|
4110.45
(-69.83%)
|
Target met |
Buy
|
|
|
|
|
29 Jun 2022
|
Dr. Reddy's Labs
|
Axis Direct
|
1240.20
|
4750.00
|
4364.35
(-71.58%)
|
Target met |
Buy
|
|
|
We recommend a BUY rating on the stock with a TP of Rs 4,750.
|
|
24 Jun 2022
|
Dr. Reddy's Labs
|
ICICI Securities Limited
|
1240.20
|
4925.00
|
4294.90
(-71.12%)
|
Target met |
Buy
|
|
|
DRL has devised a two-pronged strategy to drive long-term growth, classified as Horizon 1 and Horizon 2. Horizon 1 – Growing the core, short-medium term drivers of growth. ? Horizon 2 Building the future, short-long term drivers of growth
|
|
23 Jun 2022
|
Dr. Reddy's Labs
|
Geojit BNP Paribas
|
1240.20
|
5026.00
|
4309.65
(-71.22%)
|
Pre-Bonus/ Split |
Buy
|
|
|
|
|
22 Jun 2022
|
Dr. Reddy's Labs
|
BOB Capital Markets Ltd.
|
1240.20
|
4450.00
|
4309.65
(-71.22%)
|
Target met |
Hold
|
|
|
DRRD unveiled a framework to make its business future ready
|
|
22 Jun 2022
|
Dr. Reddy's Labs
|
Prabhudas Lilladhar
|
1240.20
|
4900.00
|
4294.90
(-71.12%)
|
Target met |
Buy
|
|
|
|
|
22 Jun 2022
|
Dr. Reddy's Labs
|
ICICI Direct
|
1240.20
|
4960.00
|
4260.90
(-70.89%)
|
Target met |
Buy
|
|
|
|
|
21 May 2022
|
Dr. Reddy's Labs
|
Sharekhan
|
1240.20
|
5550.00
|
4390.50
(-71.75%)
|
Pre-Bonus/ Split |
Buy
|
|
|
|
|
20 May 2022
|
Dr. Reddy's Labs
|
SMC online
|
1240.20
|
|
4249.10
(-70.81%)
|
Pre-Bonus/ Split |
Results Update
|
|
|
|
|
20 May 2022
|
Dr. Reddy's Labs
|
ICICI Direct
|
1240.20
|
4800.00
|
4249.10
(-70.81%)
|
Target met |
Buy
|
|
|
|